| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Santacruzamate A (also known as CAY10683) is a potent and selective inhibitor of HDAC (histone deacetylase) with IC50 of 119 pM for HDAC2, it exhibits >3600-fold selectivity over other HDACs. Santacruzamate A is a cyanobacterium isolate that shares a number of structural characteristics with suberoylanilide hydroxamic acid [SAHA, trade name Vorinostat], a histone deacetylase (HDAC) inhibitor that is approved for use in clinical settings and is used to treat refractory cutaneous T-cell lymphoma. With relatively little inhibition of HDAC4 or HDAC6, both Class II HDACs, Santacruzamate A is a picomolar level selective inhibitor of HDAC2, a Class I HDAC.
| Targets |
HDAC2 ( IC50 = 119 pM ); HDAC6 ( IC50 = 434 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
Three HDAC isozymes (HDAC2, HDAC4, and HDAC6) have had their percent inhibition and IC50 values measured using fluorogenic HDAC assay kits and commercially available human recombinant enzyme. In a nutshell, a 96-well microtiter plate with a black bottom and flat bottom is filled with the inhibitor, and the reaction mixture is then incubated for 30 minutes at 37°C. To initiate the release of the fluorophore and stop deacetylation, the assay kit contains trichostatin A, a potent HDAC inhibitor, which is added to the bifunctional HDAC assay developer at a final reaction concentration of 1 μM. A further 15 minutes are spent incubating the reaction mixture at room temperature. A Spectra Max Gemini XPS is used to measure fluorescence. Its excitation wavelength is 360 nm, and its detection wavelength is 460 nm.
|
|
| Cell Assay |
HuT-78 cells were cultured in Dulbecco's modified Iscove's medium, which was enhanced with 1% L-glutamine, 1% penicillin/streptomycin, and 20% FBS. McCoy's 5A medium supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% nonessential amino acids was used to cultivate HCT-116 cells. A 96-well plate was seeded with 5000 cells per well. The plates were incubated for 24 hours at 37°C with 5% CO2 prior to treatment. Using SAHA as a positive control, inhibitor treatments were incubated in wells for 72 or 96 hours. A typical MTS-PMS assay was used to measure the antiproliferative activity.
|
|
| Animal Protocol |
Liver Metastasis Model[2]
Female BALB/c nude mice (4–5 weeks old) were used in this experiment. Mice were injected into the tail veil with cells (2 × 10~6 cells for shRNA, 8 mice/group). After 35 days, the mice were sacrificed. Liver metastatic nodules were examined macroscopically or detected in paraffin, sectioned, and stained with H&E. As for the survival assay, mice were injected into the tail veil with cells (2 × 106 cells for shRNA, 10 mice/group). As for the treating assay, mice were injected with SW620 (2 × 106 cells/mouse) injected into the tail veil (8 mice/group). After one week, CAY10683 (Santacruzamate A) (3 mg/kg) was given intravenously (i.v.) once every three days. GSK3326595 (100 mg/kg, twice daily) was given i.v. once every ten days. After 35 days, the mice were sacrificed. Then, nodules were paraffin-embedded, sectioned, and stained with H&E. |
|
| References | ||
| Additional Infomation |
Santacruzamate A is an organooxygen compound and an organonitrogen compound. It is functionally related to a gamma-amino acid.
santacruzamate A has been reported in Cyanobacterium and Symploca with data available. |
| Molecular Formula |
C15H22N2O3
|
|
|---|---|---|
| Molecular Weight |
278.35
|
|
| Exact Mass |
278.163
|
|
| Elemental Analysis |
C, 64.73; H, 7.97; N, 10.06; O, 17.24
|
|
| CAS # |
1477949-42-0
|
|
| Related CAS # |
|
|
| PubChem CID |
72946782
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.1±0.1 g/cm3
|
|
| Boiling Point |
508.1±43.0 °C at 760 mmHg
|
|
| Flash Point |
261.1±28.2 °C
|
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
|
| Index of Refraction |
1.515
|
|
| Source |
Cyanobacterium; Panamanian Marine Cyanobacterium; Symploca.
|
|
| LogP |
1.85
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
9
|
|
| Heavy Atom Count |
20
|
|
| Complexity |
289
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(C([H])([H])C([H])([H])C([H])([H])N([H])C(=O)OC([H])([H])C([H])([H])[H])N([H])C([H])([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
|
| InChi Key |
HTOYBIILVCHURC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H22N2O3/c1-2-20-15(19)17-11-6-9-14(18)16-12-10-13-7-4-3-5-8-13/h3-5,7-8H,2,6,9-12H2,1H3,(H,16,18)(H,17,19)
|
|
| Chemical Name |
ethyl N-[4-oxo-4-(2-phenylethylamino)butyl]carbamate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO+ 30%PEG300+ 5%Tween 80Click to Order+ 60%ddH2O: 10.0mg/ml (35.93mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5926 mL | 17.9630 mL | 35.9260 mL | |
| 5 mM | 0.7185 mL | 3.5926 mL | 7.1852 mL | |
| 10 mM | 0.3593 mL | 1.7963 mL | 3.5926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Molecular-phylogenetic inference of the SCA-producing strain PAC-19-FEB-10-1 (GenBank acc. nr. JX458089.1, highlighted with an arrow).J Nat Prod.2013 Nov 22;76(11):2026-33. |
|---|
 SAHA (2) binds to HDAC enzymes such that the phenyl cap sits above the enzyme pocket into which the aliphatic chain inserts, positioning the hydroxamic acid adjacent to the enzymatic zinc at the distal end of the pocket.J Nat Prod.2013 Nov 22;76(11):2026-33. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA